- Juno has had an undeniably strong year—and the company is rewarding its top executives for the progress. CEO Hans Bishop has received a $450,000 bonus while CFO Steve Harr nabbed $200,000.
- In addition, both hold millions of share of Juno Therapeutics' stock, which is trading at a high of $47.94 based on last night's close.
- Last December, Juno had the biggest biotech IPO of 2014, raising a total of $265 million and watching its shares appreciate 60% from a $38 IPO price within one day.
Juno is at the forefront of the CAR-T oncology revolution in which therapies are being developed that modify the genes in patients' T cells in order to turn them into cancer-targeting and killing cells. The bonuses that Juno's management are receiving are well-earned based on the goals that they are being benchmarked against. For example, according to the Puget Sound Business Journal, Hans Bishop achieved 120% of his goals.
The success goes beyond simply paying the top execs nice bonuses. Thanks to their success, Juno has generated jobs in the greater Seattle area, including 50 open positions.